131 related articles for article (PubMed ID: 12562652)
1. Economic evaluation of antibiotic prophylaxis in small-cell lung cancer patients receiving chemotherapy: an EORTC double-blind placebo-controlled phase III study (08923).
Tjan-Heijnen VC; Caleo S; Postmus PE; Ardizzoni A; Burghouts JT; Buccholz E; Biesma B; Gorlia T; Crott R; Giaccone G; Debruyne C; Manegold C;
Ann Oncol; 2003 Feb; 14(2):248-57. PubMed ID: 12562652
[TBL] [Abstract][Full Text] [Related]
2. Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: an EORTC double-blind placebo-controlled phase III study.
Tjan-Heijnen VC; Postmus PE; Ardizzoni A; Manegold CH; Burghouts J; van Meerbeeck J; Gans S; Mollers M; Buchholz E; Biesma B; Legrand C; Debruyne C; Giaccone G;
Ann Oncol; 2001 Oct; 12(10):1359-68. PubMed ID: 11762805
[TBL] [Abstract][Full Text] [Related]
3. Standard versus intensified chemotherapy with granulocyte colony-stimulating factor support in small-cell lung cancer: a prospective European Organization for Research and Treatment of Cancer-Lung Cancer Group Phase III Trial-08923.
Ardizzoni A; Tjan-Heijnen VC; Postmus PE; Buchholz E; Biesma B; Karnicka-Mlodkowska H; Dziadziuszko R; Burghouts J; Van Meerbeeck JP; Gans S; Legrand C; Debruyne C; Giaccone G; Manegold C;
J Clin Oncol; 2002 Oct; 20(19):3947-55. PubMed ID: 12351591
[TBL] [Abstract][Full Text] [Related]
4. Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study.
Timmer-Bonte JN; de Boo TM; Smit HJ; Biesma B; Wilschut FA; Cheragwandi SA; Termeer A; Hensing CA; Akkermans J; Adang EM; Bootsma GP; Tjan-Heijnen VC
J Clin Oncol; 2005 Nov; 23(31):7974-84. PubMed ID: 16258098
[TBL] [Abstract][Full Text] [Related]
5. Editorial comments on 'Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: an EORTC double-blind placebo-controlled phase III study'.
Bunn PA
Ann Oncol; 2001 Oct; 12(10):1339-40. PubMed ID: 11762802
[No Abstract] [Full Text] [Related]
6. Phase I study of simultaneous dose escalation and schedule acceleration of cyclophosphamide-doxorubicin-etoposide using granulocyte colony-stimulating factor with or without antimicrobial prophylaxis in patients with small-cell lung cancer.
Ardizzoni A; Pennucci MC; Danova M; Viscoli C; Mariani GL; Giorgi G; Venturini M; Mereu C; Scolaro T; Rosso R
Br J Cancer; 1996 Oct; 74(7):1141-7. PubMed ID: 8855989
[TBL] [Abstract][Full Text] [Related]
7. Cost effectiveness of increasing the dose intensity of chemotherapy with granulocyte colony-stimulating factor in small-cell lung cancer: based on data from the Medical Research Council LU19 trial.
Bojke L; Sculpher M; Stephens R; Qian W; Thatcher N; Girling D
Pharmacoeconomics; 2006; 24(5):443-52. PubMed ID: 16706570
[TBL] [Abstract][Full Text] [Related]
8. The impact of therapy with filgrastim (recombinant granulocyte colony-stimulating factor) on the health care costs associated with cancer chemotherapy.
Glaspy JA; Bleecker G; Crawford J; Stoller R; Strauss M
Eur J Cancer; 1993; 29A Suppl 7():S23-30. PubMed ID: 7508727
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of adding granulocyte colony-stimulating factor to primary prophylaxis with antibiotics in small-cell lung cancer.
Timmer-Bonte JN; Adang EM; Smit HJ; Biesma B; Wilschut FA; Bootsma GP; de Boo TM; Tjan-Heijnen VC
J Clin Oncol; 2006 Jul; 24(19):2991-7. PubMed ID: 16682725
[TBL] [Abstract][Full Text] [Related]
10. Reply to the article "Editorial comments on 'reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: an EORTC double-blind placebo-controlled phase III study'", by P. A. Bunn Jr (Ann Oncol 2001; 12: 1339-1340).
Tjan-Heijnen VC; Postmus PE; Ardizzoni A;
Ann Oncol; 2002 Mar; 13(3):485-6; author reply 486-7. PubMed ID: 11996485
[No Abstract] [Full Text] [Related]
11. Modeling the cost effectiveness of secondary febrile neutropenia prophylaxis during standard-dose chemotherapy.
Timmer-Bonte JN; Adang EM; Termeer E; Severens JL; Tjan-Heijnen VC
J Clin Oncol; 2008 Jan; 26(2):290-6. PubMed ID: 18182670
[TBL] [Abstract][Full Text] [Related]
12. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer.
Crawford J; Ozer H; Stoller R; Johnson D; Lyman G; Tabbara I; Kris M; Grous J; Picozzi V; Rausch G
N Engl J Med; 1991 Jul; 325(3):164-70. PubMed ID: 1711156
[TBL] [Abstract][Full Text] [Related]
13. Phase III study of intensive weekly chemotherapy with recombinant human granulocyte colony-stimulating factor versus standard chemotherapy in extensive-disease small-cell lung cancer. The Japan Clinical Oncology Group.
Furuse K; Fukuoka M; Nishiwaki Y; Kurita Y; Watanabe K; Noda K; Ariyoshi Y; Tamura T; Saijo N
J Clin Oncol; 1998 Jun; 16(6):2126-32. PubMed ID: 9626212
[TBL] [Abstract][Full Text] [Related]
14. Incidence of neutropenic fever in patients treated with standard-dose combination chemotherapy for small-cell lung cancer and the cost impact of treatment with granulocyte colony-stimulating factor.
Nichols CR; Fox EP; Roth BJ; Williams SD; Loehrer PJ; Einhorn LH
J Clin Oncol; 1994 Jun; 12(6):1245-50. PubMed ID: 7515413
[TBL] [Abstract][Full Text] [Related]
15. High dose-intensity chemotherapy, with accelerated cyclophosphamide-doxorubicin-etoposide and granulocyte-macrophage colony stimulating factor, in the treatment of small cell lung cancer.
Ardizzoni A; Venturini M; Crinò L; Sertoli MR; Bruzzi P; Pennucci MC; Mariani GL; Garrone O; Bracarda S; Rosso R
Eur J Cancer; 1993; 29A(5):687-92. PubMed ID: 8385970
[TBL] [Abstract][Full Text] [Related]
16. Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer.
Masuda N; Fukuoka M; Kudoh S; Matsui K; Kusunoki Y; Takada M; Nakagawa K; Hirashima T; Tsukada H; Yana T
J Clin Oncol; 1994 Sep; 12(9):1833-41. PubMed ID: 7521905
[TBL] [Abstract][Full Text] [Related]
17. Cost-Effectiveness Analysis of Prophylaxis Treatment Strategies to Reduce the Incidence of Febrile Neutropenia in Patients with Early-Stage Breast Cancer or Non-Hodgkin Lymphoma.
Fust K; Li X; Maschio M; Villa G; Parthan A; Barron R; Weinstein MC; Somers L; Hoefkens C; Lyman GH
Pharmacoeconomics; 2017 Apr; 35(4):425-438. PubMed ID: 27928760
[TBL] [Abstract][Full Text] [Related]
18. A randomized controlled trial of sulfamethoxazole/trimethoprim plus norfloxacin versus sulfamethoxazole/trimethoprim alone for the prophylaxis of bacteria infection during chemotherapy for lung cancer.
Nagatomo A; Watanabe K; Kunikane H; Okamoto H; Kunitoh H
Lung Cancer; 1998 Feb; 19(2):121-5. PubMed ID: 9567248
[TBL] [Abstract][Full Text] [Related]
19. Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group.
Bunn PA; Crowley J; Kelly K; Hazuka MB; Beasley K; Upchurch C; Livingston R; Weiss GR; Hicks WJ; Gandara DR
J Clin Oncol; 1995 Jul; 13(7):1632-41. PubMed ID: 7602352
[TBL] [Abstract][Full Text] [Related]
20. Costs associated with intravenous chemotherapy administration in patients with small cell lung cancer: a retrospective claims database analysis.
Duh MS; Reynolds Weiner J; Lefebvre P; Neary M; Skarin AT
Curr Med Res Opin; 2008 Apr; 24(4):967-74. PubMed ID: 18282373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
